Core lab Research Use Only products

At Roche, as a leader in in vitro diagnostics, we are deeply committed to sustained innovation, as demonstrated by our industry-leading R&D investment. Research Use Only (RUO) products accelerate evidence generation and market acceptance of biomarkers not linked to a specific intended use.

Therefore, a key area of our investment is in the development of research use only medical devices to gain a better understanding of disease biology in critical high medical value areas such as:

• Neurology
• Oncology
• Infectious diseases (ID)
• Immunology
• Cardiovascular disease

By addressing the unmet needs of today's patients, we are equipping scientists with the tools to explore innovative solutions, enhance disease understanding, and refine treatment guidelines, ultimately improving patient care

Through RUO products, we ensure Roche stays at the forefront of research and enables scientists to gain insights into critical high-medical-value areas. We are committed to identifying additional biomarkers to advance scientific knowledge in areas like cardiac diseases and on MassSpec.

By enabling today's research, our RUO products are paving the way for improved patient outcomes and advanced healthcare practices tomorrow.

Roche`s RUO products currently offer a comprehensive panel for neurodegeneration research, including key established biomarkers like:^1-4

• Elecsys® pT217 RUO: An in vitro quantitative immunoassay for the measurement of tau phosphorylated at amino acid 217 (pT217P) in human plasma.
• Elecsys® ApoE4 RUO: A qualitative immunoassay for the in vitro determination of Apolipoprotein E4 (ApoE4) in human plasma.
• Elecsys® GFAP: An in vitro quantitative immunoassay for the measurement of GFAP in human serum, plasma, and cerebrospinal fluid (CSF).
• Elecsys® NfL: A quantitative immunoassay for the in vitro determination of neurofilament light (NfL) protein in human plasma, serum, and cerebrospinal fluid (CSF).

We are committed to further building our RUO products portfolio to support research and advance scientific knowledge across multiple critical disease areas, including oncology, cardiometabolic conditions, women’s health, and immunology. Some of the innovative biomarkers we are exploring for the future include:

• Amyloid beta 42 (Aß42)*
• Neuronal Pentraxin 2 (NPTX2)*
• Chitinase-3-like protein 1 (YKL-40)*
• Brain-derived tau (BD-tau)*
• Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2)*
• Synaptosomal Associated Protein 25 (SNAP-25)*
• Pro-surfactant protein B (Pro-SPB)*

Roche is not just a provider of laboratory research products such as advanced assays, but a dedicated partner. When a promising biomarker gains attention in the scientific community, we can offer it as an RUO, enabling you to harness these innovations and translate them into impactful scientific progress.

The Elecsys® RUO assays utilize electrochemiluminescence immunoassay (ECLIA) technology. They can be seamlessly integrated into your lab utilizing Roche’s automated cobas® e 801 and cobas® e 402 immunoassay analyzers.